Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Zoology Department, Faculty of Science, Zagazig University, Zagazig, Egypt.
Asian Pac J Cancer Prev. 2022 May 1;23(5):1761-1768. doi: 10.31557/APJCP.2022.23.5.1761.
Ovarian cancer is the fifth leading cause of cancer-related deaths among women worldwide. Unfortunately, early detection tests are relatively lacking. Diagnosis in the late stages of the disease carries a poor prognosis.
To evaluate the relationship between miR-196a-2 rs11614913 polymorphism and ovarian cancer risk and prognosis in Egyptian females.
In this case-control study, the participants were classified into 2 groups. Group A is the control group which included 50 healthy females. Group B included 50 patients newly diagnosed with ovarian carcinoma confirmed by histopathological analysis. Immunohistochemistry for P53 and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for miR-196a-2 genotypes detection were performed. Results: There was a statistically significant difference among ovarian cancer cases and controls regarding genotypes (P = 0.003). However, the distribution of the T and C alleles in both studied groups showed no significant difference (P = 0.17). There was a statistically significant increase of CA 125 levels among CT and CC genotypes carriers of ovarian cancer cases (p = 0.04). Besides, there was a statistically significant correlation between miR-196a-2 polymorphism and each of tumor grade (P <0.001), p53 immunohistochemical expression (P= 0.002), and Figo classification (P <0.001).
There was a statistically significant increase of CA 125 levels among C allele carriers of ovarian cancer cases. Besides, there was a statistically significant association between the miR-196a-2 polymorphism and each of tumor grade, p53 immunohistochemical expression, and Figo classification. So, miR-196a-2 polymorphism can be a possible prognostic factor in ovarian cancer.
卵巢癌是全球女性癌症相关死亡的第五大主要原因。不幸的是，早期检测方法相对缺乏。疾病晚期的诊断预后较差。
评估 miR-196a-2 rs11614913 多态性与埃及女性卵巢癌风险和预后的关系。
在这项病例对照研究中，参与者被分为两组。A 组为对照组，包括 50 名健康女性。B 组包括 50 名经组织病理学分析确诊为卵巢癌的新发病例。进行 P53 免疫组化和 miR-196a-2 基因型检测的聚合酶链反应-限制性片段长度多态性（PCR-RFLP）。
卵巢癌病例和对照组在基因型方面存在统计学显著差异（P=0.003）。然而，两组中 T 和 C 等位基因的分布无显著差异（P=0.17）。卵巢癌病例 CT 和 CC 基因型携带者的 CA125 水平有统计学显著升高（p=0.04）。此外，miR-196a-2 多态性与肿瘤分级（P<0.001）、p53 免疫组化表达（P=0.002）和 FIGO 分期（P<0.001）均存在统计学显著相关性。
卵巢癌病例 C 等位基因携带者的 CA125 水平有统计学显著升高。此外，miR-196a-2 多态性与肿瘤分级、p53 免疫组化表达和 FIGO 分期均存在统计学显著相关性。因此，miR-196a-2 多态性可能是卵巢癌的一个潜在预后因素。
